China's NMPA: Guiding Opinions & Q&A on Standardising Modern Pharmaceutical Logistics

China’s National Medical Products Administration (NMPA) has published "Guiding Opinions on the Standardization of Modern Pharmaceutical Logistics” together with an official Q&A (both dated 25 March 2026). The original NMPA publications are available only in Chinese.

The documents are intended to support the development of China’s pharmaceutical distribution sector by promoting more consistent and standardised expectations for modern pharmaceutical logistics.

According to the Q&A, the initiative also addresses the fact that provincial requirements have differed in practice, and the NMPA is aiming to provide a more uniform and operationally practical national baseline to help standardise market access and regulatory oversight for pharmaceutical wholesale and third-party logistics activities.

Key elements highlighted include:

• A clarified definition of “modern pharmaceutical logistics”, emphasising end-to-end quality control and traceability supported by an independent computerised information management system. 
• Expectations for data-driven traceability aligned with national traceability standards, supporting verifiable origin and destination of medicinal products. 
• Requirements for warehouse set-up and functional zoning, including temperature-controlled storage concepts.
• Explicit attention to transport and cold chain controls, including monitoring of vehicles.

The Q&A further clarifies that the Guiding Opinions function as a technical guidance document, intended both to guide companies when establishing wholesale operations or conducting third-party logistics activities, and to support provincial regulators in licensing access, renewals, and routine inspections.